China NMPA Drug Inspection - Xiantao Yaozui Renhe Hospital - safflower

The Hubei Provincial Food and Drug Administration conducted a comprehensive drug quality supervision and sampling inspection during the fourth quarter of 2014, with results announced on March 19, 2015. This extensive oversight covered 143 drug and pharmaceutical packaging material producers, 1440 distribution enterprises, and 1112 medical institutions across Hubei Province.Out of 1580 drug varieties and 4681 batches sampled, a significant 162 varieties and 368 batches were found to be substandard. The primary issues identified across various Traditional Chinese Medicine (TCM) processed slices and a few Western medicines included non-compliance with quality standards for properties, identification, and various inspection parameters. Common violations involved incorrect physical characteristics, issues with microscopic or chromatographic identification, and failures in purity tests such as moisture content, total ash, acid-insoluble ash, and impurities. Specific instances also highlighted the presence of unauthorized substances like auramine O, colorants (Acid Red 73), or excessive sulfur dioxide residue. A recurring problem noted was products being falsely attributed to manufacturers ("Not produced by this company"), indicating potential counterfeit or unauthorized sourcing.The regulatory framework underpinning these inspections includes the "Drug Administration Law of the Republic of China" and the "Chinese Pharmacopoeia 2010 Edition," alongside supplementary testing methods. Local food and drug administrations are mandated to conduct intensified investigations, legally address the non-compliant products, trace the origins and distribution channels of counterfeit drugs, and implement rigorous follow-up sampling and testing to ensure public safety and product integrity.